BackAnaptysBio Overview

AnaptysBio Long Term Debt

Track AnaptysBio's long-term debt ($280M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$275.24M
1921.85% YoYΔ $261.62M vs prior year quarter

Peer trimmed avg / median

Loading

AnaptysBio Long Term Debt History

Loading

AnaptysBio vs. peers: Long Term Debt Comparison

Loading

AnaptysBio Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AnaptysBio (ANAB) FAQ

As of the most recent data (March 2026), ANAB shows a long-term debt of $280M. That compares with $14M in the prior-year period — up 1921.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ANAB's long-term debt is now $280M (was $14M) — a 1921.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether AnaptysBio is outperforming or lagging.

Tracking ANAB's long-term debt over time shows whether AnaptysBio is scaling, shrinking, or reshaping that part of the business. The current reading is $280M That compares with $14M in the prior-year period — up 1921.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has AnaptysBio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $280M) with ownership activity and broader fundamentals.

AnaptysBio's long-term debt is $280M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.